Patients
340 outpatients who were ≥ 18 years of age (mean age 42 y, 66% women); had a current diagnosis of MDD; and scored ≥ 20 on the Hamilton Depression Rating Scale (HDRS) (mean score 22.8) and ≤ 60 on the Global Assessment of Functioning (mean score 53.6) after a 1 week placebo run in period. Exclusion criteria included a score > 2 on the HDRS suicide item, serious physical or psychiatric disorders, use of psychoactive drugs, and pregnancy. Follow up was 99%.
Intervention
Patients were allocated to 1 of 3 groups: SJW, 900 mg/day of 0.12-0.28% hypericin (n=113); sertraline, 50 mg/day (n=111); or placebo (n=116). The main highest daily doses were 1299 mg for SJW and 75 mg for sertraline during the first 8 weeks; after 8 weeks, the respective mean highest daily doses were 1382 mg and 89 mg.
Main outcome measures
Change from baseline HDRS score and full response (Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2 and HDRS score ≤ 8) at week 8. Secondary outcomes included CGI scores and relapse (HDRS score ≥ 20 and CGI-Severity score ≥ 4 on 2 consecutive visits) during the continuation phase.
Main results
Analysis was by intention to treat. SJW (mean score change -8.7) and sertraline (mean score change -10.5) were not better than placebo (mean score change -9.2) for change from baseline in HDRS scores or clinical response (table) . SJW led to more anorgasmia (p=0.04), frequent urination (p=0.003), and swelling (p=0.02) than placebo (table) . Sertraline led to more diarrhoea (38% v 19%, p=0.003), nausea (37% v 21%, p=0.02), anorgasmia (32% v 14%, p=0.002), and sweating (29% v 12%, p=0.003) than placebo. Sertraline was better than placebo for CGI-I score at 8 weeks (mean score 2.04 v 2.45, p=0.02). 1 patient in the SJW group relapsed during the continuation phase.
Conclusion
In patients with major depressive disorder, Hypericum perforatum (St John's wort) was not better than placebo for reducing symptoms. 
COMMENTARY
Herbal remedies, especially old ones, are appealing. SJW has been widely used for depression. Previous studies have compared various SJW preparations with low doses of a standard antidepressant or have reported a large placebo effect. 1 The study by the Hypericum Depression Trial Study Group was intended to address these problems.
The results appear inconclusive: neither treatment differed from placebo. However, sertraline was inadequately dosed at the mean maximum of 75 mg/day (recommended dose 50-200 mg/day). Yet it was better than placebo on the CGI, with many partial responders and few side effects, so a higher dose may have been effective. The inadequate use of sertraline in this otherwise well designed and conducted study is hard to understand. The SJW dose was generous, with no hint of a response over placebo. The robust placebo response, consistent with mild or transient depression, showed why placebo controlled studies are necessary in this field. 2 SJW is generally well tolerated, but problems can include anorgasmia, serotonin syndrome, photosensitivity, and hair loss. 3 4 The active ingredient(s) may be hypericin, hyperforin, or something else. 5 SJW can induce cytochrome p450s, 2D6, and 3A4, potentially reducing concentrations of oral contraceptives, antineoplastic and antiretroviral agents, and other drugs. 1 5 Yet, 74% of SJW users had not sought medical advice. 4 In conclusion, the best study of SJW to date found it no better than placebo. Its pharmacological effects and active ingredients are not established. It may have substantial pharmacokinetic interactions, yet is generally used without medical supervision. Its use may preclude or delay accurate diagnosis and more effective treatment. St John's wort may not be effective, but it is not innocuous.
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